What it is
Tazarotene is a different retinoid molecule from tretinoin, historically the most potent of the class and the most irritating. Arazlo repackages it as a 0.045% lotion in a polymeric emulsion that meters the drug out gradually, cutting the irritation that made older tazarotene hard to stay on. It carries an FDA indication for moderate-to-severe acne at ages 9 and up, applied once nightly.
In two phase 3 trials, inflammatory lesions dropped 55.5% and 59.5% by week 12, versus 45.7% and 49.0% with the vehicle lotion alone (both p<0.001). Tolerability was the headline result: 14.7% of Arazlo patients had a treatment-emergent adverse event versus 26.8% on the older Tazorac 0.1% cream. Head-to-head data from older formulations show once-daily tazarotene beating once-daily tretinoin on papules and open comedones, with faster pustule reduction.
The catch is price. No generic exists for the 0.045% lotion, so the cash price is high; a manufacturer copay card can bring commercially insured patients to zero after deductible, and generic tazarotene 0.1% cream is a far cheaper route to the same molecule in an older vehicle. Trials judged results at 12 weeks, and the first-month dryness curve looks like any retinoid's.
Who this fits
- Breakouts that held on through a real 12-week tretinoin or adapalene run
- Comedone-heavy skin: head-to-head data favor tazarotene on open comedones and papules
- You quit older Tazorac from irritation and want the lotion's slower delivery
- Commercial insurance that unlocks the copay card, or budget for a brand
- Not a fit if you are pregnant or planning pregnancy
How the online flow works
- 1
Intake and photos
Complete the online questionnaire and upload clear photos, including close-ups of clogged-pore areas.
- 2
Video visit
A California-licensed physician reviews your intake and photos with you live and weighs Arazlo against generic tazarotene 0.1% cream or another retinoid.
- 3
Pharmacy
The prescription is sent with the cost route settled first: copay card if your insurance qualifies, generic if not.
- 4
Follow-up
A follow-up around week 12 reviews your response against the trial timeline and adjusts.
Side effects, honestly
Honest list, not fine print. Every one of these is part of the consent conversation at your video visit.
- Retinoid-class dryness, peeling and redness; tazarotene is historically the most potent and most irritating of the class
- In phase 3 trials, 14.7% had a treatment-emergent adverse event on the lotion, versus 26.8% on the older cream
- Not used in pregnancy
- No generic lotion exists, so the fill route gets planned before anything is sent to a pharmacy
The evidence
- Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol 2020.
- Randomized comparison of once-daily tazarotene versus once-daily tretinoin in acne vulgaris. PMID 10898831.
- Reynolds RV et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2024. PMID 38300170.
Straight answers
- What does it cost?
- A prescribing visit is $79 and each follow-up is $39, itemized on the pricing page; nothing is added at checkout. The lotion is the expensive part: brand only, with cash prices in the facts above, so the visit settles a plan (copay card or generic tazarotene cream) before the prescription goes out.
- Is tazarotene stronger than tretinoin?
- Historically it is the most potent topical retinoid, and head-to-head data from older formulations show once-daily tazarotene beating once-daily tretinoin on papules and open comedones, with faster pustule reduction. Potency cuts both ways: it earned a reputation for irritation, which the Arazlo lotion vehicle cuts roughly in half by adverse-event rate versus the older cream.
- Why is Arazlo so expensive, and what are the outs?
- No generic exists for the 0.045% lotion. The Bausch Health copay card can bring commercially insured patients to $0 after deductible at participating pharmacies, and generic tazarotene 0.1% cream delivers the same molecule for far less; the visit covers which route fits you.
- How long until I see results?
- The phase 3 trials judged results at 12 weeks, with inflammatory lesions down 55.5% and 59.5% versus 45.7% and 49.0% on vehicle. Expect the standard retinoid dryness curve first: worst in the opening weeks, fading as skin adapts.
- Can I use it while on isotretinoin?
- Usually not. Oral isotretinoin already works the retinoid pathway and dries skin substantially, so a topical retinoid on top mostly adds irritation without clear gain. It is a case-by-case call for the physician at your visit.